Karah Parschauer

Karah Parschauer is recorded as General Counsel at Ultragenyx Pharmaceutical Inc. (RARE) and Board Member at Tenaya Therapeutics, Inc. (TNYA) since September 12, 2024. The newest filing on record that lists Karah Parschauer as General Counsel at Ultragenyx Pharmaceutical Inc. (RARE) is dated April 29, 2021. The newest filing on record that lists Karah Parschauer as Board Member at Tenaya Therapeutics, Inc. (TNYA) is dated April 16, 2026. Earlier roles on record: Board Member at Arcturus Therapeutics Holdings Inc. (ARCT) until August 25, 2021. Tenaya Therapeutics, Inc. reported in an 8-K filed May 29, 2026 that Karah Parschauer was appointed Class II Director, effective May 27, 2026. Tenaya Therapeutics, Inc. reported in an 8-K filed September 16, 2024 that Karah Parschauer was appointed Class II director, effective September 12, 2024. Tenaya Therapeutics, Inc. reported in an 8-K filed September 16, 2024 that Karah Parschauer resigned as Class I director, effective September 12, 2024. The proxy statement of Ultragenyx Pharmaceutical Inc. reports total compensation of $3,509,313 for Karah Parschauer in fiscal 2025, including a base salary of $585,342. Disclosed compensation is on record for 2 fiscal years. Tenaya Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Ultragenyx Pharmaceutical Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Tenaya Therapeutics, Inc. includes Faraz Ali (CEO, CFO and Board Member), Eric Hyllengren (CFO), Chihiro Saito (Chief Accounting Officer) and 7 others.